Search

Your search keyword '"Medical Oncology"' showing total 159,941 results
Start Over Author "Medical Oncology"

Refine your results

more »

more »

more »

more »

more »

more »
159,941 results on '"Medical Oncology"'

1. Endoprosthesis vs. nail-cement spacer application for reconstruction after oncologic proximal humeral resection: is there a difference in functional outcome?

Author

Sandeep Sehrawat, MS (Orthopedics), Abhijit Behera, MS (Orthopedics), Love Kapoor, MS (Orthopedics), Venkatesan Sampath Kumar, MS (Orthopedics), DNB (Orthopedics), MRCS, FRCS (Tr & Orth Glasg), Sameer Bakhshi, MD, DM (Medical Oncology), and Shah Alam Khan, MS (Orthopedics), DNB (Orthopedics), MRCS (Edi), MChOrth (Liverpool)

Subjects
Proximal humerus tumors, Nail-cement spacer reconstruction, Endoprosthesis reconstruction, Limb salvage surgery, Oncologic resections, Functional outcomes, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
Abstract

Background: The proximal humerus is a common site for primary malignant and benign aggressive bone tumors, necessitating wide resection and subsequent skeletal defect reconstruction. Various reconstruction options include osteoarticular allografts, autografts, endoprosthesis, nail-cement spacer, reverse shoulder arthroplasty, and allograft-prosthesis composites. However, there is no consensus on the optimal reconstruction method. This study aims to compare functional outcomes and complications between these two methods. Methods: A total of 40 patients with proximal humerus tumors who underwent endoprosthesis or nail-cement spacer reconstruction between March 2012 and December 2020 were included. The mean follow-up in the study was 31.37 +/− 12 months. Demographic and clinical data were collected, and functional outcomes were assessed using the Musculoskeletal Tumor Society 93 scoring system and the Disabilities of the Arm, Shoulder, and Hand questionnaire. Complications and oncological outcomes were recorded. Results: Both groups were similar in terms of demographic and clinical variables. Endoprosthesis reconstruction demonstrated significantly better active shoulder forward flexion compared to nail-cement spacer (45.8 vs. 25.2 degrees) (P = .015). Endoprosthesis group also exhibited greater active shoulder internal rotation (68.25 vs. 63.25 degrees) (P = .004). No statistically significant differences were observed in overall functional outcomes. Complications, including radial nerve palsy and infection, were comparable between groups, with one case of spacer loosening. Conclusion: Both endoprosthesis and nail-cement spacer reconstruction provide comparable functional outcomes and complication rates following proximal humerus tumor resection. Nail-cement spacer offers a cost-effective alternative for patients in resource-constrained settings.

Published
2024
Full Text
View/download PDF

2. Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment (PRedICT-TOPIC)

Author

ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Olijf: Dutch patient association for women with gynaecological cancer, Leids Universitair Medisch Centrum: Department of Medical Oncology and Department of Pathology, Maastricht Universitair Medisch Centrum: Department of Gynaecology and Department of Pathology, Erasmus Medisch Centrum: Department of Gynaecology, Radboud Medisch Centrum: Department of Gynaecology, and Edith van Esch, Principal Investigator, gynaecologist

Published
2023

5. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

Author

Koehler, Philipp, Bassetti, Matteo, Chakrabarti, Arunaloke, Chen, Sharon CA, Colombo, Arnaldo Lopes, Hoenigl, Martin, Klimko, Nikolay, Lass-Flörl, Cornelia, Oladele, Rita O, Vinh, Donald C, Zhu, Li-Ping, Böll, Boris, Brüggemann, Roger, Gangneux, Jean-Pierre, Perfect, John R, Patterson, Thomas F, Persigehl, Thorsten, Meis, Jacques F, Ostrosky-Zeichner, Luis, White, P Lewis, Verweij, Paul E, Cornely, Oliver A, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, and Infectious Disease Canada

Subjects
European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.

Published
2021

10. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Author

Irfan Cicin, Ergun Oksuz, Nuri Karadurmus, Simten Malhan, Mahmut Gumus, Ulku Yilmaz, Levent Cansever, Halit Cinarka, Erdogan Cetinkaya, Murat Kiyik, Ahmet Ozet, Lung Cancer Report Study Group Turkey, on behalf of the Turkish Society of Lung Cancer, Lung Health and Intensive Care Association, University of Health Sciences, Turkish Society of Medical Oncology, National Cancer Institute, and Turkish Respiratory Society

Subjects
Lung cancer, Practice patterns, Cost of illness, Direct costs, Indirect costs, Economic burden, Medicine (General), R5-920
Abstract

Abstract Background This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.

Published
2021
Full Text
View/download PDF

12. Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Author

Rush University Medical Center, Stormont-Vail Healthcare, Jefferson Medical College of Thomas Jefferson University, The Cleveland Clinic, Sparrow Health System, Cancer & Hematology Centers of Western Michigan (CHCWM), Allegheny Health Network, St. Luke's Hospital and Health Network, Pennsylvania, Solano Hematology Oncology, Horizon Oncology Center, Comprehensive Blood and Cancer Center, Lancaster Cancer Center, Western Maryland Health Center, Valley Medical Oncology, Cape Fear Valley Health System, Tri-County Hematology Oncology, Hematology & Oncology Associates, Broome Oncology, Orchard Healthcare, Ashland Bellefonte Cancer Center, Tennessee Cancer Specialists, North Shore Hematology Oncology, Good Samaritan, Zangmeister Cancer Center, Watson clinic, Oncology Consultants, Oncology Hematology Care, Northern Westchester Hospital, and Peter MacCallum Cancer Center Trials Unit

Published
2018

13. Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study

Author

Lucie Probst, Enrico Schalk, Tobias Liebregts, Vanja Zeremski, Asterios Tzalavras, Michael von Bergwelt-Baildon, Nina Hesse, Johanna Prinz, Jörg Janne Vehreschild, Alexander Shimabukuro-Vornhagen, Dennis A. Eichenauer, Jorge Garcia Borrega, Matthias Kochanek, Boris Böll, and for the Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)

Subjects
Sepsis, SIRS, Sepsis-3, qSOFA, Cancer, Hematological malignancies, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Abstract Background With Sepsis-3, the increase in sequential organ failure assessment (SOFA) as a clinical score for the identification of patients with sepsis and quickSOFA (qSOFA) for the identification of patients at risk of sepsis outside the intensive care unit (ICU) were introduced in 2016. However, their validity has been questioned, and their applicability in different settings and subgroups, such as hematological cancer patients, remains unclear. We therefore assessed the validity of SOFA, qSOFA, and the systemic inflammatory response syndrome (SIRS) criteria regarding the diagnosis of sepsis and the prediction of in-hospital mortality in a multicenter cohort of hematological cancer patients treated on ICU and non-ICU settings. Methods We retrospectively calculated SIRS, SOFA, and qSOFA scores in our cohort and applied the definition of sepsis as “life-threatening organ dysfunction caused by dysregulated host response to infection” as reference. Discriminatory capacity was assessed using the area under the receiver operating characteristic curve (AUROC). Results Among 450 patients with hematological cancer (median age 58 years, 274 males [61%]), 180 (40%) had sepsis of which 101 (56%) were treated on ICU. For the diagnosis of sepsis, sensitivity was 86%, 64%, and 42% for SIRS, SOFA, and qSOFA, respectively. However, the AUROCs of SOFA and qSOFA indicated better discrimination for sepsis than SIRS (SOFA, 0.69 [95% CI, 0.64–0.73] p

Published
2019
Full Text
View/download PDF

15. Exploring the Score Equivalence of the English and Chinese Versions of the Brief Assessment Scale for Caregivers

Author

Grace Meijuan Yang MBBChir, MA, MRCP, MPH, Shirlyn Hui-Shan Neo MBBS, MMed(Int Med), MRCP, Irene Teo MS, PhD, Geok Ling Lee BSocSci, MSocSci, PhD, Julian Thumboo MBBS, MMed (Int Med), FRCP (Edin), FAMS (Rheumatology), John Chia MBBS, MRCP, FAMS (Medical Oncology), Annie Lau BHSN, MN, Audrey Koh BSc, Debra Qu MSN, William Wai Lam Che BA, MA, MPhil, Hwee Lin Wee PhD, Myra Glajchen DSW, and Yin Bun Cheung PhD, Cstat

Subjects
Medicine (General), R5-920
Abstract

Background: Multilingual outcome measures are used so that research studies are more generalizable across language contexts. Objective: To determine the score equivalence of the English and Chinese versions of Brief Assessment Scale for Caregivers (BASC) in Singapore. Method: Caregivers of patients with advanced cancer completed the BASC in either English or Chinese. Multivariable linear regression analysis was used to compare the mean BASC total and factor scores between the 2 language versions, with adjustment for possible confounding variables. Equivalence was declared if the 90% confidence interval of the mean scores fell entirely within an equivalence zone of ±0.5 standard deviation. Results: There were 521 ethnic Chinese participants, of whom 214 answered the English version and 307 answered the Chinese version. The BASC total and factor scores met the criteria for equivalence. Cronbach α coefficients were similar and exploratory factor analysis showed similar 2-factor structures for both language versions. Conclusion: The English and Chinese versions of the BASC were found to be equivalent in terms of similar adjusted mean scores, Cronbach α, and factor structures.

Published
2020
Full Text
View/download PDF

16. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S)

Author

Aventis Pharmaceuticals, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Gruppo Oncologico Italiano di Ricerca Clinica, Gruppo Oncologico del Nord-Ovest, Italian Trial in Medical Oncology, Southern Italy Cooperative Oncology Group, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, and Oncotech

Published
2014

25. Geriatric oncology in Spain: survey results and analysis of the current situation

Author

Gironés, R., Morilla, I., Guillen-Ponce, C., Torregrosa, M. D., Paredero, I., Bustamante, E., del Barco, S., Soler, G., Losada, B., Visa, L., Llabrés, E., Fox, B., Firvida, J. L., Blanco, R., Antonio, M., Aparisi, F., Pi-Figueras, M., Gonzalez-Flores, E., Molina-Garrido, M. J., Saldaña, J., and On behalf of the Spanish Working Group on Geriatric Oncology of the Spanish Society of Medical Oncology (SEOM)

Published
2018
Full Text
View/download PDF

26. Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study

Author

Probst, Lucie, Schalk, Enrico, Liebregts, Tobias, Zeremski, Vanja, Tzalavras, Asterios, von Bergwelt-Baildon, Michael, Hesse, Nina, Prinz, Johanna, Vehreschild, Jörg Janne, Shimabukuro-Vornhagen, Alexander, Eichenauer, Dennis A., Garcia Borrega, Jorge, Kochanek, Matthias, Böll, Boris, and for the Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)

Published
2019
Full Text
View/download PDF

27. Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM)

Author

Sbardella, E., Isidori, A. M., Arnaldi, G., Arosio, M., Barone, C., Benso, A., Berardi, R., Capasso, G., Caprio, M., Ceccato, F., Corona, G., Della Casa, S., De Nicola, L., Faustini-Fustini, M., Fiaccadori, E., Gesualdo, L., Gori, S., Lania, A., Mantovani, G., Menè, P., Parenti, G., Pinto, C., Pivonello, R., Razzore, P., Regolisti, G., Scaroni, C., Trepiccione, F., Lenzi, A., Peri, A., and On behalf of the: Fluid and Electrolyte Disorders Club of the Italian Society of Endocrinology; Italian Society of Nephrology; and Italian Association of Medical Oncology

Published
2017
Full Text
View/download PDF

28. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

Author

Carmona-Bayonas, A., Jiménez-Fonseca, P., Virizuela, J., Antonio, M., Font, C., Biosca, M., Ramchandani, A., Martinez-Garcia, J., Hernando, J., Espinosa, J., de Castro, E. M., Ghanem, I., Beato, C., Blasco, A., Garrido, M., Mondéjar, R., Arcusa, M. Á., Aragón, I., Manzano, A., Sevillano, E., Castañón, E., Ayala, F., and On behalf of the Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM)

Published
2017
Full Text
View/download PDF

32. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Author

Ullmann, Andrew J., Schmidt-Hieber, Martin, Bertz, Hartmut, Heinz, Werner J., Kiehl, Michael, Krüger, William, Mousset, Sabine, Neuburger, Stefan, Neumann, Silke, Penack, Olaf, Silling, Gerda, Vehreschild, Jörg Janne, Einsele, Hermann, Maschmeyer, Georg, and on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)

Published
2016
Full Text
View/download PDF

34. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

Author

Baykara, Meltem, Benekli, Mustafa, Ekinci, Ozgur, Irkkan, Sultan Cigdem, Karaca, Halit, Demirci, Umut, Akinci, Muhammed Bulent, Unal, Olcun Umit, Dane, Faysal, Turkoz, Fatma Paksoy, Balakan, Ozan, Eser, Eylem Pinar, Ozturk, Selcuk Cemil, Ozkan, Metin, Oksuzoglu, Berna, Sevinc, Alper, Demir, Necla, Harputluoglu, Hakan, Yalcin, Bulent, Coskun, Ugur, Uner, Aytug, Ozet, Ahmet, Buyukberber, Suleyman, and for the Anatolian Society of Medical Oncology (ASMO)

Published
2015
Full Text
View/download PDF

35. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Kompetenznetz Komplementärmedizin In Der Onkologie-KOKON, CAM-Cancer, Schweizerische Gesellschaft Für Medizinische Onkologie, Society Of Medical Oncology (Schweiz), Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Krebsforschung Schweiz, and Krebsliga Schweiz

Subjects
Medizin und Gesundheit
Published
2022
Full Text
View/download PDF

38. Androgenski receptori: nejasan sveprisutan mehanizam ili ključ koji nedostaje u trostruko negativnom raku dojke?

Author

Tečić-Vuger, Ana, Medical Oncology Department, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia, Šeparović, Robert, Vazdar, Ljubica, Pavlović, Mirjana, Lepetić, Petra, Šitić, Sanda, Šarčević, Božena, and Vrbanec, Damir

Subjects
androgenski receptori, rak prostate, rak dojke, trostruko negativni rak dojke, business.industry, Mechanism (biology), androgen receptors, breast cancer, triple negative breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prostate cancer, triple–negative breast cancer, Androgen receptor, androgen receptors, breast cancer, Oncology, Key (cryptography), Cancer research, Medicine, business, RC254-282, Triple-negative breast cancer
Abstract

Androgen receptors (AR) are ligand-dependent nuclear transcription factors. These are steroid receptors, similar to estrogen receptors (ER). They are expressed in numerous cells in the body, with different constructive roles. AR signalling can be involved in the development of a variety of human malignant tumors, such as prostate cancer, bladder, liver, salivary glands, kidney, lung, melanoma, sarcoma, breast cancer, and many others. The role of AR is most clear and today best explained in prostate cancer. The mechanism of AR signalling in other human epithelial tumors is still quite unclear and the effects are different to entirely opposite in different tumors. In breast cancer, AR are the most commonly expressed receptors, but still with an incompletely clear role, prognostic and predictive significance. The expression of AR in triple-negative breast cancer (TNBC) is highly variable. Despite the marked differences in the results of the various analyzes, they appear to have a beneficial effect on the prognosis and are potentially the target of antihormone therapy for treatment of TNBC in the future., Androgenski receptori (AR) su jezgrini prepisivački čimbenici ovisni o ligandu. To su steroidni receptori, slični estrogenskim receptorima (ER). Izraženi su u brojnim stanicama s različitim gradivnim ulogama. AR signalizacija može biti uključena u razvoj različitih zloćudnih tumora, poput raka prostate, mokraćnog mjehura, jetre, žlijezda slinovnica, bubrega, pluća, melanoma, sarkoma, raka dojke i mnogih drugih. Uloga AR najjasnija je i najbolje objašnjena u raku prostate. Mehanizam AR signalizacije u drugim humanim epitelnim tumorima još je uvijek nejasan i učinci su kod različitih tumora različiti, sve do potpuno oprečnih. U raku dojke AR su najčešće izraženi receptori, ali još uvijek s nepotpuno jasnom ulogom, prognostičkim i prediktivnim značajem. Izraženost AR u trostruko negativnom raku dojke (TNBC) vrlo je varijabilna. Unatoč izraženim razlikama u rezultatima različitih analiza, čini se da blagotvorno utječu na prognozu i potencijalna su meta antihormonske terapije za liječenje TNRD u budućnosti.

Published
2020

39. Response of the Istituto Nazionale Tumori of Milan Head & Neck Cancer Unit to the COVID-19 outbreak

Author

Carlo Resteghini, Paola Maggioni, Vito Di Martino, Lisa Licitra, and on behalf of Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, General surgery, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Outbreak, COVID-19, Head neck cancer, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Radiation therapy, Editorial, medicine, Head and neck surgery, Pharmacology (medical), business
Abstract

In a time of uncertainties such the present days, we all look for guiding principles. When no guidelines are available, principles shape our actions. Above all, do no harm has been ours as we are facing the largely unknown challenge of the global COVID-19 epidemic. This mentality guided our efforts to strike the balance between reducing exposure of patients and health care providers to risk of infection on the one hand, and on the other, meeting our daily goal of providing optimal oncologic treatment in a tertiary center of national relevance.

Published
2020

41. Bisphosphonates and osteonecrosis of the jaw

Author

Australian Dental Association, Osteoporosis Australia, Australian and New Zealand Bone and Mineral Society, Medical Oncology Group of Australia, Sambrook, P, Olver, I, and Goss, A

Published
2006

43. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

Author

Elkiran, Emin Tamer, Kaplan, Mehmet Ali, Sevinc, Alper, Aksoy, Sercan, Demirci, Umut, Seker, Mesut, Harputluoglu, Hakan, Ozdemir, Nuriye Yildirim, Isik, Feridun, Ulas, Arife, Inanc, Mevlude, Arslan, Ulku Yalcintas, Dogu, Gamze Gokoz, Isikdogan, Abdurrahman, Buyukberber, Suleyman, and Anatolian Society of Medical Oncology Group

Published
2012
Full Text
View/download PDF

44. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

Author

Tonyali, Onder, Coskun, Ugur, Sener, Nur, Inanc, Mevlude, Akman, Tulay, Oksuzoglu, Berna, Ozdemir, Nuriye Yildirim, Yazilitas, Dogan, Benekli, Mustafa, Uner, Aytug, Yamac, Deniz, Demirci, Umut, Yildiz, Ramazan, Karaca, Halit, Unal, Olcun Umit, Bal, Oznur, Gumus, Mahmut, Buyukberber, Suleyman, and Anatolian Society of Medical Oncology (ASMO)

Published
2012
Full Text
View/download PDF

45. Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer

Author

Gouvas, N. Gourtsoyianni, S. Kalogeridi, M.A. Sougklakos, J. Vini, L. Xynos, E. the Hellenic Society of Medical Oncology (HESMO)

Abstract

Despite considerable improvement in the management of anal cancer, there is a great deal of variation in the outcomes among European countries, and in particular among different hospital centres in Greece and Cyprus. The aim was to elaborate a consensus on the multidisciplinary management of anal cancer, based on European guidelines (European Society of Medical Oncologists-ESMO), considering local special characteristics of our healthcare system. Following discussion and online communication among members of an executive team, a consensus was developed. Guidelines are proposed along with algorithms of diagnosis and treatment. The importance of centralisation, care by a multidisciplinary team (MDT) and adherence to guidelines are emphasised. © 2020, Italian Society of Surgery (SIC).

Published
2021

46. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics

Author

Dana-Farber Cancer Institute - Department of Medical Oncology, Harvard University - Ludwig Center at Harvard, Daniels, Veerle W., Zoeller, Jason J., Van Gastel, Nick, McQueeney, Kelley E., Parvin, Salma, Potter, Danielle S., Fell, Geoffrey G., Ferreira, Vinícius G., Yilma, Binyam, Gupta, Rajat, Spetz, Johan, Bhola, Patrick D., Endress, Jennifer E., Harris, Isaac S., Carrilho, Emanuel, Sarosiek, Kristopher A., Scadden, David T., Brugge, Joan S., Letai, Anthony, Dana-Farber Cancer Institute - Department of Medical Oncology, Harvard University - Ludwig Center at Harvard, Daniels, Veerle W., Zoeller, Jason J., Van Gastel, Nick, McQueeney, Kelley E., Parvin, Salma, Potter, Danielle S., Fell, Geoffrey G., Ferreira, Vinícius G., Yilma, Binyam, Gupta, Rajat, Spetz, Johan, Bhola, Patrick D., Endress, Jennifer E., Harris, Isaac S., Carrilho, Emanuel, Sarosiek, Kristopher A., Scadden, David T., Brugge, Joan S., and Letai, Anthony

Abstract

Cancer cells have differential metabolic dependencies compared to their nonmalignant counterparts. However, few metabolism-targeting compounds have been successful in clinical trials. Here, we investigated the metabolic vulnerabilities of triple-negative breast cancer (TNBC), particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics (drugs that antagonize antiapoptotic proteins). We used high-throughput dynamic BH3 profiling (HT-DBP) to screen a library of metabolism-perturbing small molecules, which revealed inhibitors of the enzyme nicotinamide phosphoribosyltransferase (NAMPT) as top candidates. In some TNBC cells but not in nonmalignant cells, NAMPT inhibitors increased overall apoptotic priming and induced dependencies on specific antiapoptotic BCL-2 family members. Treatment of TNBC cells with NAMPT inhibitors sensitized them to subsequent treatment with BH3 mimetics. The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient-derived xenograft model in vivo. We found that NAMPT inhibition reduced NAD+ concentrations below a critical threshold that resulted in depletion of adenine, which was the metabolic trigger that primed TNBC cells for apoptosis. These findings demonstrate a close interaction between metabolic and mitochondrial apoptotic signaling pathways and reveal that exploitation of a tumor-specific metabolic vulnerability can sensitize some TNBC to BH3 mimetics.

Published
2021

47. What is new in Systemic treatment of TN early and advanced BC?

Author

7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology (October 16, 2021), Sotiriou, Christos, 7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology (October 16, 2021), and Sotiriou, Christos

Abstract

info:eu-repo/semantics/nonPublished

Published
2021

48. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., Stacchiotti, Silvia, European Society for Medical Oncology, Strauss, S. J., Frezza, Anna M., Abecassis, N., Bajpai, J., Bauer, Sebastian, Biagini, R., Bielack, S., Blay, Jean-Yves, Bolle, S., Bonvalot, Sylvie, Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, Bernadette, Brodowicz, T., Buonadonna, A., Álava, Enrique de, Dei Tos, Angelo Paolo, García del Muro, Xavier, Dufresne, Armelle, Eriksson, Mikael, Fagioli, F., Fedenko, Alexander, Ferraresi, Virginia, Ferrari, A., Gaspar, Nathalie, Gasperoni, Silvia, Gelderblom, Hans, Gouin, Francois, Grignani, Giovanni, Gronchi, Alesandro, Haas, R. L., Hassan, A. B., Hecker-Nolting, S., Hindi, Nadia, Hohenberger, Peter, Joensuu, Heikki, Jones, Robin L., Jungels, C., Jutte, P., Kager, L., Kasper, Bernd, Kawai, Akira, Kopeckova, K., Krákorová, D. A., Le Cesne, Axel, Le Grange, F., Legius, E., Leithner, Andreas, López-Pousa, Antonio, Martín-Broto, Javier, Merimsky, O., Messiou, C., Miah, A. B., Mir, Olivier, Montemurro, M., Morland, B., Morosi, Carlo, Palmerini, Emanuela, Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, Peter, Rutkowski, Piotr, Safwat, A. A., Sangalli, C., Sbaraglia, Marta, Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, Michiel, van der Graaf, W. T., van Houdt, W. J., Frebourg, T., Ladenstein, Rudolf, Casali, Paolo G., and Stacchiotti, Silvia

Published
2021

49. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

Author

Celio, Luigi, Frustaci, Sergio, Denaro, Angela, Buonadonna, Angela, Ardizzoia, Antonio, Piazza, Elena, Fabi, Alessandra, Capobianco, Alba Maria, Isa, Luciano, Cavanna, Luigi, Bertolini, Alessandro, Bichisao, Ettore, Bajetta, Emilio, and for the Italian Trials in Medical Oncology Group

Published
2011
Full Text
View/download PDF

50. Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer

Author

Kaya, Ali Osman, Buyukberber, Suleyman, Benekli, Mustafa, Coskun, Ugur, Sevinc, Alper, Akmansu, Muge, Yildiz, Ramazan, Ozturk, Banu, Yaman, Emel, Kalender, Mehmet Emin, Orhan, Okan, Yamac, Deniz, Uner, Aytug, and for Anatolian Society of Medical Oncology (ASMO)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results